Laboratory Diagnosis of Some Components of Metabolic Syndrome

N.M. Kobyliak, D.V. Kyriienko

Abstract


Metabolic syndrome is a complex of interrelated risk factors for cardiovascular diseases and diabetes mellitus. The prevalence of metabolic syndrome grows progressively all over the world due to the increased number of people with obesity and unhealthy lifestyle. The article presents the definition of insulin resistance and disorders in endocrine function of adipose tissue as major pathogenetic links that unite the main clusters of metabolic syndrome. It is shown that metabolic syndrome is a complex medical problem which should to be aimed at reducing the prevalence of obesity, increased physical activity of population and early detection in order to modify risk factors leading to the development of type 2 diabetes mellitus and cardiovascular diseases.


Keywords


metabolic syndromes; insulin resistance

References


Reaven G.M. Role of insulin resistance in human disease / G.M. Reaven // Diabetes. — 1988. — V. 37. — P. 1595-1607.

Kaplan N.M. The deadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension / N.M. Kaplan // Arch. Intern. Med. — 1989. — V. 149. — P. 1514-1520.

Henefeld M. Das metabolische Syndrome. Deutsch / M. Henefeld, W. Leonhardt // Ges. Wes. — 1980. — V. 36. — P. 545-551.

DeFronzo R.A. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture, 2009 / R.A. DeFronzo // Diabetologia. — Vol. 53, № 7. — Р. 1270-1287.

Body mass index and mortality in a prospective cohort of US adults / E.E. Calle, M.J. Thun, J. M. Petrelli [et al.] // N. Engl. J. Med. — 1999. — Vol. 341. — P. 1097-1105.

The disease burden associated with overweight and obesity / A. Must, J. Spadano, E.H. Coakley // JAMA. — 1999. — Vol. 282. — P. 1523-1529.

Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR) / E. Ferrannini, A. Natali, P. Bell [et al.] // J. Clin. Invest. — 1997. — Vol. 100. — P. 1166-1173.

What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? / M. Brochu, A. Tchernof, I.J. Dionne [et al.] // J. Clin. Endocrinol. Metab. — 2001. — Vol. 86. — P. 1020-1025.

The metabolically healthy but obese individual presents a favorable inflammation profile / A.D. Karelis, M. Faraj, J.P. Bastard [et al.] // J. Clin. Endocrinol. Metab. — 2005. — Vol. 90. — P. 4145-4150.

Karelis A.D. Can we identify metabolically healthy but obese individuals (MHO)? / A.D. Karelis, M. Brochu, R. Rabasa-Lhoret // Diabetes Metab. 2004. — Vol. 30. — P. 569-572.

Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease / J.B. Meigs, P.W. Wilson, C.S. Fox // J. Clin. Endocrinol. Metab. — 2006. — Vol. 91. — P. 2906-2912.

Impaired fasting glucose and impaired glucose tolerance: implication for care / D.M. Narthan, M.B. Davidson, R.A. De Fronzo [et al.] // Diabetes Care. — 2007. — Vol. 30. — P. 753-759.

Identification of individuals with insulin resistance using routine measurements / S.E. Stern, K. Williams, E. Ferranini [et al.] // Diabetes. — 2005. — Vol. 54. — P. 333-339.

The International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes // Diabetes Care. — 2009. — Vol. 32, № 7. — P. 1327-1334.

American Diabetes Associations. Diagnosis and classification of diabetes mellitus // Diabetes Care. — 2010. — S. suppl. 1. — S. 62-69.

Строев Ю.И., Цой М.В., Чурилов Л.П., Шишкин А.Н. Классические и современные представления о метаболическом синдроме. Ч. 2. Патогенез // Вестн. С.-Петерб. ун-та. — Сер. 11, Вып. 4. — 2007. — С. 3-15.

Bjorntorp P. «Portal» adipose tissue as the generator of risk factors for cardiovascular disease and diabetes / P. Bjorntorp // Arteriosclerosis. — 1990. — Vol. 10. — P. 493-496.

Lipoprotein lipase regulation by insulin and glucocorticoid in subcutaneous and omental adipose tissues from obese women and men / S.K. Fried, C.D. Russsell, N.L. Grauso, R.E. Brolin // J. Clin. Invest. — 1991. — Vol. 92. — P. 2191-2198.

Glucocorticoids down-regulate glucose uptake capacity and insulin-signalling proteins in omental but not subcutaneous adipocytes / M. Lundgren, J. Buren, T. Ruge [et al.] // J. Clin. Endocrinol. Metab. — 2004. — Vol. 89. — P. 2989-2997.

Малижев В.О. Дисфункція жирової тканини як вирішальний чинник розвитку цукрового діабету 2 типу // Здоров’я України. — 2007. — № 10/1.

The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus / P.J. Randle, P.B. Garland, C.N. Hales, E.A. Newsholme // Lancet. — 1963. — Vol. 13, № 1. — Р. 785-789.

Effect of long chain triglyceride infusion on glucose metabolism in man / D. Thiebaud, R. A. DeFronzo, E. Jacot [et al.] // Metabolism. — 1982. — Vol. 31, № 11. — Р. 1128-1136.

Effect of fatty acids on glucose production and utilization in man / E. Ferrannini, E.J. Barrett, S. Bevilacqua, R.A. DeFronzo // Journal of Clinical Investigation. — 1983. — Vol. 72, № 5. — Р. 1737-1747.

Interaction between glucose and free fatty acid metabolism in human skeletal muscle / D.E. Kelley, M. Mokan, J.A. Simoneau, L.J. Mandarino // Journal of Clinical Investigation. — 1993. — Vol. 92, № 1. — Р. 91-98.

Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity / A. Dresner, D. Laurent, M. Marcucci [et al.] // Journal of Clinical Investigation. — 1999. — Vol. 103, № 2. — Р. 253-259.

Shulman G.I. Cellular mechanisms of insulin resistance / G.I. Shulman // Journal of Clinical Investigation. — 2000. — Vol. 106, № 2. — Р. 171-176.

Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance / W.L. Holland, J.T. Brozinick, L.P. Wang [et al.] // Cell Metab. — 2008. — Vol. 5. — P. 167-179.

Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB / D. Cai, M. Yuan, D.F. Frantz // Natю Med. — 2005. — Vol. 11. — P. 183-190.

Groop L.C. Insulin resistance and insulin deficiency in the pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus: errors of metabolism or of methods? / L.C. Groop, E. Widйn, E. Ferrannini // Diabetologia. — 1993. — Vol. 36, № 12. — P. 1326-1331.

Майоров А.Ю. Методы количественной оценки инсулинорезистентности / А.Ю. Майоров, К.А. Урбанова, Г.Р. Галстян // Ожирение и метаболизм. — 2009. — № 2. — С. 19-23.

Алишева Е.К. Методы ранней диагностики инсулинорезистентности / Е.К. Алишева, Е.И. Красильникова, Е.В. Шляхто // Артериальная гипертензия. — 2002. — Т. 8, № 1. — С. 29-34.

DeFronzo R.A. Glucose clamp technique: a method for quantifying insulin secretion and resistance / R.A. DeFronzo, J.D. Tobin, R. Andres // American Journal of Physiology. — 1979. — Vol. 237, № 3. — P. 214-223.

Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man / D.R. Matthews, J.P. Hosker, A.S. Rudenski [et al.] // Diabetologia. — 1985. — Vol. 28, № 7. — P. 412-419.

Wallace T.M. Use and abuse of HOMA modeling / T.M. Wallace, J.C. Levy, D.R. Matthews // Diabetes Care. — 2004. — Vol. 27, № 6. — P. 1487-1495.

Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity / E. Bonora, G. Targher, M. Alberichie [et al.] // Diabetes Care. — 2000. — Vol. 23. — P. 57-63.

Comparison of several insulin sensitivity indices derived from basal plasma insulin and glucose levels with minimal model indices / D.A. Garcia-Estevez, D. Araujo-Vilar, G. Fiestras-Janeiro // Horm. Metab. Res. — 2003. — Vol. 35. — P. 13-17.

Инсулиновая резистентность и роль гормонов жировой ткани в развитии сахарного диабета: пособие для врачей / Дедов И.И., Балаболкин М.И., Мамаева Г.Г. [и др.] // М., 2005. — 88 с.

Friedman J.M. Leptin at 14 y of age: an ongoing story / J.M. Friedman // Am. J. Clin. Nutr. — 2009. — Vol. 89(Suppl.). — P. 973-979.

Identification and expression cloning of a leptin receptor, OB-R / L.A. Tartaglia, M. Dembski, X. Weng [et al.] // Cell. — 1995. — Vol. 83. — P. 1263-1271.

A novel leptin receptor isoform in rat / M.Y. Wang, Y. Zhou, C.B. Newgard, R.H. Unger // FEBS Lett. — 1998. — Vol. 392. — P. 87-90.

Abnormal splicing of the leptin receptor in diabetic mice / G.H. Lee, R. Proenca, J.M. Montez [et al.] // Nature. — 1996. — Vol. 379. — P. 632-635.

Minokoshi Y. Role of AMP-activated protein kinase in leptin-induced fatty acid oxidation in muscle / Y. Minokoshi, B.B. Kahn // Biochem. Soc. Trans. — 2003. — Vol. 31. — P. 196-201.

AMPK expression and phosphorylation are increased in rodent muscle after chronic leptin treatment / G.R. Steinberg, J.W.E. Rush, D.J. Dyck // Am. J. Physiol. Endocrinol. Metab. — 2003. — Vol. 284. — P. 648-654.

Mohammed J. Adipokines and pathogenesis of non-alcoholic fatty liver disease / J. Mohammed, Y. Zobair // AnCha Baranova. — 2008. — 192 p.

Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression / G.M. Lord, G. Matarese, J.K. Howard [et al.] // Nature. — 1998. — Vol. 394, № 6696. — P. 897-901.

Globular adiponectin decreases leptin-induced tumor necrosis factor-α expression by murine macrophages: involvement of cAMP-PKA and MAPK pathways / T. Zhao, M. Hou, M. Xia [et al.] // Cell Immunol. — 2005. — Vol. 238, № 1. — P. 19-30.

Leptin enhances TNF-α production via p38 and JNK MAPK in LPS-stimulated Kupffer cells / J. Shen, I. Sakaida, K. Uchida [et al.] // Life Sci. — 2005. — Vol. 77. — P. 1502–1515.

Leptin-deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity: role of tumor necrosis factor-б and ІЛ-18 / R. Faggioni, J. Jones-Carson, D.A. Reed [et al.] // Proc. Natl Acad. Sci. USA. — 2000. — Vol. 97, № 5. — P. 2367-2372.

Requirement for leptin in the induction and progression of autoimmune encephalomyelitis / G. Matarese, A. Di Giacomo, V. Sanna [et al.] // J. Immunol. — 2001. — Vol. 166, № 10. — P. 5909-5916.

Gorden P. The clinical uses of leptin / P. Gorden, O. Gavrilova // Curr. Opin. Pharmacol. — 2003. — Vol. 3. — P. 655-659.

Кобиляк Н.М. Патофізіологічна роль лептину у розвитку ожиріння та супутніх захворювань / Н.М. Кобиляк, М.М. Кондро, О.В. Вірченко, Т.М. Фалалєєва // Експериментальна та клінічна фізіологія і біохімія. — 2013. — № 3 (63). — С. 55-63.

Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity / U.B. Pajvani, X. Du, T.P. Combs [et al] // J. Biol. Chem. — 2003. — Vol. 278, № 11. — P. 9073-9085.

Патофізіологічна роль адипонектину в розвитку ожиріння та супутніх захворювань / Н.М. Кобиляк, Г.П. Михальчишин, О.А. Савченюк, Т.М. Фалалєєва // Світ медицини та біології. — 2013. — № 3(40), ч. 2. — С. 81-87.

Михальчишин Г.П. Гіпоадипонектинемія у хворих на цукровий діабет типу 2 з неалкогольною жировою хворобою печінки / Г.П. Михальчишин, П.М. Боднар, Н.М. Кобиляк // Ендокринологія. — 2013. — Т. 18, № 2. — С. 18-25.

Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity / U.B. Pajvani, M. Hawkins, T.P. Combs [et al.] // J. Biol. Chem. — 2004. — Vol. 279, № 13. — Vol. 12152-12162.

Changes of adiponectin oligomer composition by moderate weight reduction / T. Bobbert, H. Rochlitz, U. Wegewitz [et al.] // Diabetes. — 2005. — Vol. 54, № 5. — P. 2712-2719.

Cloning of adiponectin receptors that mediate antidiabetic metabolic effects / T. Yamauchi, J. Kamon, Y. Ito [et al.] // Nature. — 2003. — Vol. 423, № 6941. — P. 762-769.

Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome / T. Kadowaki, N. Yamauchi, N. Kubota [et al.] // J. Clin. Invest. — 2006. — Vol. 116, № 7. — P. 1784-1792.

Tilg H. Adipocytokines: mediators linking adipose tissue, inflammation and immunity / H. Tilg, A.R. Moschen // Nat. Rev. Immunol. — 2006. — Vol. 6, № 10. — P. 772-783.

Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population / K. Hara, P. Boutin, Y. Mori [et al.] // Diabetes. — 2002. — Vol. 51. — P. 536-540.

Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocytesecreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians / F. Vasseur, N. Helbecque, C. Dina [et al.] // Hum. Mol. Genet. — 2002. — Vol. 11. — P. 2607-2614.

Single nucleotide polymorphisms in the proximal promoter region of the adiponectin (APM1) gene are associated with type 2 diabetes in Swedish Caucasians / H.F. Gu, A. Abulaiti, C.G. Ostenson [et al.] // Diabetes. — 2004. — Vol. 53 (Suppl. 1). — P. 31-35.

Adiponectin — a key adipokine in the metabolic syndrome / J.P. Whitehead, A.A. Richards, I.J. Hickman // Diabetes Obes. Metab. — 2006. — Vol. 8, № 3. — P. 264-280.

Disruption adiponectin causes insulin resistance neo-intimal formation / N. Kubota, Y. Terauchi, T. Yamauchi [et al.] // J. Biol. Chem. — 2002. — Vol. 277. — P. 25863-25866.

Diet-induced insulin resistance in mice lacking adiponectin/ACRP30 / N. Maeda, I. Shimomura, K. Kishida [et al.] // Nat. Med. — 2002. — Vol. 8. — P. 731-737.

A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity / T.P. Combs, U.B. Pajvani, A.H. Berg [et al.] // Endocrinology. — 2004. — Vol. 145. — P. 367-383.

Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase / T. Yamauchi, J. Kamon, Y. Minokoshi [et al.] // Nature Med. — 2002. — Vol. 8, № 11. — P. 1288-1295.

Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes / A.M. Wolf, D. Wolf, H. Rumpold [et al.] // Biochem. Biophys. Res. Commun. — 2004. — Vol. 323. — P. 630-635.

Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin / H.N. Kobayashi, S. Ouchi, K. Kihara [et al.] // Circ. Res. — 2004. — Vol. 94, № 4. — P. 27-31.

Retraction / A. Fukuhara, M. Matsuda, M. Nishizawa [et al.] // Science. — 2007. — Vol. 318, № 5850. — P. 565.

Visfatin: a protein secreted by visceral fat that mimics the effects of insulin / A. Fukuhara, M. Matsuda, M. Nishizawa [et al.] // Science. — 2005. — Vol. 307, № 5708. — P. 426-430.

Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor / B. Samal, Y. Sun, G. Stearns [et al.] // Mol. Cell. Biol. — 2007. — Vol. 14. — P. 1431-1437.

Visfatin, an adipocytokine with proinflammatory and immunomodulating properties / A. R. Moschen, A. Kaser, B. Enrich [et al.] // J. Immunol. — 2007. — Vol. 178. — P. 1748-1758.

Plasma visfatin concentrations and fat depot-specific mRNA expression in humans / J. Berndt, N. Kloting, S. Kralisch [et al.] // Diabetes. — 2005. — Vol. 54. — P. 2911-2916.

Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance / T. Dogru, A. Sonmez, I. Tasci [et al.] // Diabetes Res. Clin. Pract. — 2005. — Vol. 76. — P. 24-29.

Tilg H. Cytokines in alcoholic and non-alcoholic steatohepatitis / H. Tilg, A.M. Diehl // N. Engl. J. Med. — 2000. — Vol. 343. — Р. 1467-1476.

Михальчишин Г.П. Рівень чинника некрозу пухлин альфа і його кореляційні взаємозв’язки у хворих на цукровий діабет типу 2 із неалкогольною жировою хворобою печінки. / Г.П. Михальчишин, П.М. Боднар, Н.М. Кобиляк // Клінічна ендокринологія та ендокринна хірургія. — 2014. — № 1(46). — С. 33-40.

Tartaglia L.A. Two TNF receptors / L.A. Tartaglia, D.V. Goeddel // Immunol. Today. — 1992. — Vol. 13. — Р. 151-153.

Hotamisligil G.S. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance / G.S. Hota-misligil, N.S. Shargill, B.M. Spiegelman // Science. — 1993. — Vol. 259. — Р. 87-91.

Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function / K.T. Uysal, S.M. Wiesbrock, M.W. Marino [et al.] // Nature. — 1997. — Vol. 389. — Р. 610-614.

A central role for JNK in obesity and insulin resistance / J. Hirosumi, G. Tuncman, L. Chang [et al.] // Nature. — 2002. — Vol. 21, № 420. — P. 333-336.

Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikk-в / M. Yuan, N. Konstantopoulos, J. Lee [et al.] // Science — 2001. — Vol. 293. — P. 1673-1677.

Shoelson S.E. Inflammation and the IKK-β /I-kB/NF-κB axis in obesity- and diet-induced insulin resistance / S.E. Shoelson, J. Lee, M. Yuan // Int. J. Obes. Relat. Metab. Disord. — 2003. — Vol. 27. — P. 49-52.

Serine phosphorylation of insulin receptor substrate 1 by inhibitor κB kinase complex / Z. Gao, D. Hwang, F. Bataille [et al.] // J. Biol. Chem. — 2002. — Vol. 277. — P. 48115-48121.

Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB / D. Cai, M. Yuan, D.F. Frantz [et al.] // Nat. Med. — 2005. — Vol. 11. — P. 183-190.

Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes / R.S. Hundal, K.F. Petersen, A.B. Mayerson [et al.] // J. Clin. Invest. — 2002. — Vol. 109. — P. 1321-1326.

Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases / C.A. Dinarello // Blood. — 2011. — Vol. 117. — P. 3720-3732.

Adipose and liver expression of IL-1 family members in morbid obesity and effects of weight loss / A.R. Moschen, C. Molnar, B. Enrich [et al.] // Mol. Med. — 2011. — Vol. 17, № 7–8. — P. 840-845.

Михальчишин Г.П. Рівень ІЛ-1в та його кореляційні взаємозв’язки у хворих на цукровий діабет типу 2 із неалкогольною жировою хворобою печінки. / Г.П. Михальчишин, П.М. Боднар, Н.М. Кобиляк // Ендокринологія. — 2013. — № 4. — С. 21-28.

Interleukin-1beta may mediate insulin resistance in liver-derived cells in response to adipocyte inflammation / O. Nov, A. Kohl, E.C. Lewis et al. // Endocrinology. — 2010. — Vol. 151. — P. 4247-4256.

Interleukin-1 receptor antagonist is upregulated during diet-induced obesity and regulates insulin sensitivity in rodents / E. Somm, P. Cettour-Rose, C. Asensio [et al.] // Diabetologia. — 2006. — Vol. 49. — P. 387-393.

XOMA 052, an anti-IL-1{beta} monoclonal antibody, improves glucose control and {beta}-cell function in the diet-induced obesity mouse model / A.M. Owyang, K. Maedler, L. Gross [et al.] // Endocrinology. — 2010. — Vol. 151. — P. 2515-2527.

Interleukin-1-receptor antagonist in type 2 diabetes mellitus / C.M. Larsen, M. Faulenbach, A. Vaag [et al.] // N. Engl. J. Med. — 2007. — Vol. 356. — P. 1517-1526.

A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation / K.H. Kim, K. Lee, Y.S. Moon, H.S. Sul // J. Biol. Chem. — 2001. — Vol. 276. — P. 11252-11256.

The hormone resistin links obesity to diabetes / C.M. Steppan, S.T. Bailey, S. Bhat [et al.] // Nature. — 2001. — Vol. 409. — P. 307-312.

Banerjee R.R. Resistin: molecular history and prognosis / R.R. Banerjee, M.A. Lazar // J. Mol. Med. — 2003. — Vol. 81. — P. 218-226.

Abnormal glucose homeostasis due to chronic hyperresistinemia / S.M. Rangwala, A.S. Rich, B. Rhoades [et al.] // Diabetes. — 2004. — Vol. 53. — 1937-1941.

Adipose-derived resistin and gut-derived resistin-like molecule-selectively impair insulin action on glucose production / M.W. Rajala, S. Obici, P.E. Scherer, L. Rossetti // J. Clin. Invest. — 2005. — Vol. 111. — P. 225-230.

Adenovirus-mediated chronic ‘hyper-resistinemia’ leads to in vivo insulin resistance in normal rats / H. Satoh, M.T. Nguyen, P.D. Miles [et al.] // J. Clin. Invest. — 2004. — Vol. 114. — P. 224-231.

Loss of resistin improves glucose homeostasis in leptin deficiency / Y. Qi, Z. Nie, Y.S. Lee [et al] // Diabetes. — 2006. — Vol. 55. — P. 3083-3090.

SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-α in the adipose tissue of obese mice / B. Emanuelli, P. Peraldi, J. Filloux [et al.] // J. Biol. Chem. — 2001. — Vol. 276. — P. 47944-47949.

Nagaev J. Insulin resistence and type 2 diabetes are not related to resistin expression in human fat cells or skelet muscle / J. Nagaev, U. Smith // Biochem Biophys Re Commun. — 2001. — Vol. 285. — P. 561-564.

Increased resistin blood levels are not associated with insulin resistance in patients with renal disease / J.T. Kielstein, B. Becker, S. Graf [et al.] // Am. J. Kidney Dis. — 2003. — Vol. 42. — P. 62-66.

The interleukin-6 (-174) G/C promoter polymorphism is associated with type-2 diabetes mellitus in Native Americans and Caucasians / B. Vozarova, J.M. Fernandez-Real, W.C. Knowler [et al.] // Hum. Genet. — 2003. — V. 112. — P. 409-413.

5-amino-imidazole carboxamide riboside acutely potentiates glucose-stimulated insulin secretion from mouse pancreatic islets by KATP channeldependent and independent pathways / C. Z. Wang, Y. Wang, A. Di [et al.] // Biochem. Biophys. Res. Commun. — 2005. — V. 330. — P. 1073-1079.

Interleukin-6 acts as insulin sensitizer on glycogen synthesis in human skeletal muscle cells by phosphorylation of Ser473 of Akt / C. Weigert, A.M. Hennige, K. Brodbeck [et al.] // Am. J. Physiol. Endocrinol. Metab. — 2005. — V. 289. — P. 251-257.

Pickup J. C. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes / J.C. Pickup // Diabetes Care. — 2004. — V. 27. — P. 813-823.

Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion / B. Vozarova, C. Weyer, K. Hanson [et al.] // Obes. Res. — 2001. — V. 9. — P. 414-417.

Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro / J.P. Bastard, M. Maachi, J.T. Van Nhieu [et al.] // J. Clin. Endocrinol. Metab. — 2002. — V. 87. — P. 2084-2089.

Interleukin-6 and tumor necrosis factor — alpha are not increased in petients with Type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness / A.L. Carrey, C.R. Bruce, M. Sacchetti [et al.] // Diabetologia. — 2004. — V. 47. — P. 1029-1037.

Rotter V. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects / V. Rotter, I. Nagaev, U. Smith // J. Biol. Chem. — 2003. — V. 278. — P. 45777-45784.

Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes / M. Fasshauer, S. Kralisch, M. Klier [et al.] // Biochem. Biophys. Res. Commun. — 2003. — V. 301. — P. 1045-1050.

Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice / P.J. Klover, T.A. Zimmers, L.G. Koniaris, R.A. Mooney // Diabetes. — 2003. — V. 52. — P. 2784-2789.

Suppressor of cytokine signalling 3 expression and insulin resistance in skeletal muscle of obese and type 2 diabetic patients / J. Rieusset, K. Bouzakri, E. Chevillotte [et al.] // Diabetes. — 2004. — V. 53. — P. 2232-2241.

Interleukin-6-deficient mice develop mature-onset obesity / V. Wallenius, K. Wallenius, B. Ahren [et al.] // Nat. Med. — 2002. — V. 8. — P. 75-79.

Differential effects of interleukin-6 and-10 on skeletal muscle and liver insulin action in vivo / H.J. Kim, T. Higashimori, S.Y. Park [et al.] // Diabetes. — 2004. — V. 53. — P. 1060-1067.

Mooney R.A. Counterpoint: interleukin-6 does not have a beneficial role in insulin sensitivity and glucose homeostasis / R.A. Mooney // J. Appl. Physiol. — 2007. — V. 102. — P. 816-818.

Effect of endotoxin-induced monokines on glukose metabolism in the muscle cell line L6 / M.D. Lee, A. Zentella, W. Vine [et al.] // Proc. Natl. Alad. Sci. USA. — 1987. — V. 84. — P. 2590-2594.

Двойственная роль интерлейкина-6 в развитии инсулинорезистентности / В. Шварц // Патологическая физиология и экспериментальная терапия. — 2010. — № 1. — С. 40-47.




DOI: https://doi.org/10.22141/2224-0721.1.65.2015.75903

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru